The Penn State Milton S. Hershey Medical Center and Penn State College of Medicine are opening an institute dedicated to personalized medicine in which clinicians tailor individualized therapies according to patients’ genomic makeups, particularly for oncology patients, to produce better outcomes.
The institute, scheduled to open in June, will collaborate with other departments and institutes at the Hershey campus, including the Penn State Clinical and Translational Science Institute, to advance research in this field and to translate that research into clinical applications.
Read the fully story: http://hcp.lv/ziyIGe
Source: MEDCITY News
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More